featured
Ibrutinib, Obinutuzumab, and Venetoclax in Relapsed and Untreated Patients With Mantle Cell Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Ibrutinib, Obinutuzumab and Venetoclax in Relapsed and Untreated Patients With Mantle-Cell Lymphoma, a Phase I/II Trial
Blood 2020 Nov 12;[EPub Ahead of Print], S Le Gouill, F Morschhauser, D Chiron, K Bouabdallah, G Cartron, O Casasnovas, C Bodet-Milin, S Ragot, C Bossard, N Nadal, C Herbaux, B Tessoulin, E Tchernonog, C Rossi, R McCulloch, T Gastinne, CB Mary, S RuleFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.